S tent thrombosis (ST) is an uncommon but catastrophic complication following stent implantation associated with a high incidence of myocardial infarction (MI) and death. [1] [2] [3] Drug-eluting stents (DES) have reduced restenosis and target vessel revascularization compared with bare metal stents, but less complete strut coverage and delayed healing may predispose to increased ST with these devices. 4, 5 The correlates and consequences of ST after stent implantation have been evaluated in patient populations treated with bare metal stents and early-generation DES, 1,5-10 but there are limited studies from a more contemporary all-comers patient population, including the use of newer generation DES. 11 The Assessment of Dual Anti-Platelet Therapy With Drug-Eluting Stents (ADAPT-DES) study is the largest prospective investigation to date evaluating the correlates and consequences of ST in patients treated with DES in an all-comers population. 12 The study included a large proportion of patients treated with new-generation DES, evaluated routine testing of platelet reactivity after aspirin and clopidogrel loading, and assessed the role of intravascular ultrasound (IVUS) guidance Background-Previous studies evaluating correlates of stent thrombosis (ST) have included mostly patients with bare metal stents and early-generation drug-eluting stents (DES) and have not systematically evaluated the role of intravascular ultrasound-guided stenting and high platelet reactivity on clopidogrel. The purpose of this study was to evaluate the frequency and correlates of ST in patients receiving DES, specifically examining the impact of risk factors modifiable by physician and patient behavior. Methods and Results-Assessment of Dual Anti-platelet Therapy With Drug-Eluting Stents (ADAPT-DES) was a multicenter, prospective study in patients undergoing successful coronary intervention with DES in whom routine platelet reactivity testing was performed. Definite or probable ST occurred in 92 (1.1%) of 8582 patients within 2 years. Independent baseline correlates of ST included presentation with an acute coronary syndrome (hazard ratio [HR]=1.81, P=0.01), insulin-treated diabetes mellitus (HR=1.91, P=0.02), previous myocardial infarction (HR=1.75, P=0.02), and peripheral arterial disease (HR=2.01, P=0.01). Independent treatment-related correlates included use of early generation DES (HR=1.75, P=0.02), no procedural intravascular ultrasound guidance (HR=1.75, P=0.04), and premature discontinuation of dual antiplatelet therapy (HR=2.67, P=0.003); high platelet reactivity on clopidogrel trended as a correlate of ST (HR=1.49, P=0.08). The 2-year risk of ST ranged from 0.3% to 10.0% when 0 to 3 modifiable risk factors were present. Conclusions-After successful DES implantation, ST occurred within 2 years in 1.1% of patients and was strongly associated with fixed and modifiable risk factors. The frequency of ST may be reduced with intravascular ultrasound -guided stenting, assiduous adherence to dual antiplatelet therapy, and adequate P2Y12 platelet receptor inhibition. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00638794. (Circ Cardiovasc Interv. 2015;8:e002568.
Correlates of Stent Thrombosis
on outcomes. The purpose of the present study was to evaluate the incidence, correlates, and consequences of ST after implantation of DES in ADAPT-DES, specifically examining the impact of those risk factors modifiable by physician and patient behavior.
Methods

Study Design
ADAPT-DES was a prospective, multicenter study designed to determine the relationship between platelet reactivity after aspirin and clopidogrel loading and subsequent ST and other clinical outcomes after successful coronary DES implantation. 12 Consecutive patients treated with DES at 9 US and 2 German sites without major procedural complications who were adequately loaded with aspirin and clopidogrel were enrolled. Types of stents used included Cypher sirolimus-eluting stents (Cordis Corporation, Fremont, CA), Taxus paclitaxel-eluting stents (Boston Scientific, Natick, MA), Xience and Promus everolimus-eluting stents (Abbott Vascular, Santa Clara, CA and Boston Scientific, respectively), and Endeavor fast release and Resolute slow release zotarolimus-eluting stents (Medtronic, Minneapolis, MN). Patients with planned bypass surgery or significant anemia preventing accurate measurement of platelet reactivity were excluded. 12 Platelet reactivity was assessed using the VerifyNow Aspirin, P2Y12, and IIb/IIIa assays (Accumetrics, San Diego, CA) as previously described. 12 Following percutaneous coronary intervention, patients were treated with aspirin indefinitely, and clopidogrel was recommended for at least 1 year. Clinical follow-up was scheduled at 30 days, 1 year, and 2 years. This study was approved by the institutional review board at each participating center, and all eligible patients signed informed, written consent.
Definitions and End Points
The primary end point was definite or probable ST according to the Academic Research Consortium criteria. 13 MI was defined as the presence of clinical and electrocardiographic changes consistent with myocardial ischemia in the setting of elevated cardiac biomarkers. 12 MI was considered ST-related when occurring within 2 days of ST. Early-generation DES were defined as sirolimus-eluting stents or paclitaxel-eluting stents. Newer generation DES were defined as everolimus-eluting stents and slowrelease zotarolimus-eluting stents. Fast-release zotarolimus-eluting stents were excluded from this categorization because this stent's properties may be considered intermediate between first-and second-generation DES. Premature discontinuation of dual antiplatelet therapy (DAPT) was discontinuation before 6 months unless an ST episode had occurred earlier. An independent clinical events committee adjudicated all events.
Statistical Methods
The frequencies of ST in patients with and without baseline and treatment variables were compared with univariable Cox regression. Frequencies of ST in patients with and without selected variables were also presented as Kaplan-Meier estimates and compared with log-rank statistics. Multivariable correlates of ST were determined with Cox proportional hazards regression models. In the first models, clinically important baseline variables with univariable P values <0.1 were entered into the Cox regression model. Left ventricular ejection fraction was not included in the multivariable analyses because of missing data. In the final models, treatment variables (early-versus newer-generation DES, use versus nonuse of procedural IVUS guidance, low versus high platelet reactivity [HPR] on clopidogrel, and premature DAPT discontinuation) with univariable P values <0.1 and all significant baseline variables from the first model were entered into a Cox regression model. DAPT discontinuation was modeled as a time-dependent covariate. Stepwise selection was used to select significant predictors with entry/removal criteria of 0.1. Only clinically important variables were entered to avoid model overfitting. Analyses were performed with SPSS version 19.0 (IBM Incorporated, Armonk, NY) and SAS version 9.2 (SAS Institute, Cary, NC).
As a sensitivity analysis, all final models of time to ST were analyzed accounting for the competing risk of all-cause death, using the proportional subdistribution hazards regression described in Fine and Gray. 14 The presented hazard ratio (HR) and 2-year ST rates are consistent with the estimates from the proportional subdistribution hazards regression and the cumulative incidence of ST, respectively.
Results
Patients and Stent Thrombosis
Between January 7, 2008, and September 16, 2010, 8582 patients undergoing successful DES implantation were prospectively enrolled at 11 sites in the United States and Germany. The study population included 4433 patients (51.7%) with acute coronary syndromes (ACS) and 4149 patients (48.3%) with non-ACS. Follow-up was complete through 2 years in 89.1% (7563/8490) of patients who did not develop ST.
ST occurred in 92 patients (1.1%) within 2 years, including 72 definite and 20 probable ST. ST occurred early (≤30 days) in 39/92 cases (42.4%), late (>30 days through 1 year) in 33/92 cases (35.9%), and very late (>1 through 2 years) in 20/92 cases (21.7%; Figure 1 ).
Baseline Variables
Frequencies and HRs for 2-year ST for baseline clinical, angiographic, and treatment variables are shown in the Table. Patients with diabetes mellitus (specifically insulin-treated), previous MI, previous coronary artery bypass surgery, peripheral arterial disease, history of dialysis, presentation with ACS, ejection fraction <40%, saphenous vein graft as a target vessel, in-stent restenotic lesions, thrombus grade >0, hemoglobin <12 g/dL, and HPR on clopidogrel (VerifyNow
WHAT IS KNOWN
• Correlates of stent thrombosis (ST) following placement of first-generation drug-eluting stents and bare metal stents have been evaluated in several studies.
WHAT THE STUDY ADDS
• The study evaluates correlates of ST in a population that includes a large proportion of patients treated with new-generation drug-eluting stents.
• The study also evaluates intravascular ultrasoundguided stenting, new-generation drug-eluting stents, and high platelet reactivity on clopidogrel as potential correlates of ST. These have not been evaluated previously in studies evaluating overall correlates of ST.
• The study also evaluates the potential impact of modifiable correlates of ST (intravascular ultrasound-guided stenting, high platelet reactivity on clopidogrel, and premature discontinuation of dual antiplatelet therapy) on the frequency of ST. P2Y12 PRU >208) had significant HRs for increased rates of ST. Patients with IVUS-guided stenting and patients treated with new-versus early-generation DES had significant HRs for lower rates of ST. Patients with premature DAPT discontinuation within 6 months had a higher incidence of 6-month ST ( 
Consequences of ST
Patients who developed ST had high rates of cardiovascular mortality (30.0%) and nonperiprocedural MI (87.2%) at 2 years. Rates of cardiovascular mortality and nonperiprocedural MI were similar in ACS patients and ST (30.8% and 85.8%) and non-ACS patients with ST (28.6% and 89.5%). Most nonperiprocedural MIs occurring within 2 years in patients with ST were related to the ST episode itself; however, MIs unrelated to an ST episode also occurred more frequently in the 92 patients with ST than in those without ST (10.5% versus 2.5%).
Multivariable Correlates of 2-Year ST
As shown in Figure 4 , independent baseline fixed correlates of 2-year ST by multivariable Cox regression were insulintreated diabetes mellitus, previous MI, history of dialysis, presentation with ACS, and saphenous vein graft as a target vessel (Model 1). When modifiable treatment covariates were added to this baseline model, nonuse of IVUS for procedural guidance ( 
Multivariable Correlates of 2-Year ST in Patients Treated With New-Generation DES
Of 5442 patients treated with new-generation DES, 44 (0.8%) developed ST within 2 years. Independent baseline fixed correlates of 2-year ST by multivariable Cox regression were insulin-treated diabetes mellitus and history of peripheral arterial disease. When modifiable treatment covariates were added to this baseline model, premature DAPT discontinuation was also an independent correlate and HPR on clopidogrel trended as an independent correlate ( Figure 5 ).
Correlates of Early and Late or Very Late ST
Univariable correlates of early ST (≤30 days) and late or very late ST (>30 days to 2 years) are shown in Tables I and II 
Potential Impact of Modifiable Risk Factors on ST
Of the independent correlates of 2-year ST, not using procedural IVUS guidance, HPR on clopidogrel, and premature DAPT discontinuation are 3 risk factors that are potentially modifiable by the physician and patient. As shown in the left panel of Figure 6 , the 2-year risk of ST varied from 0.3% to 10.0% as the number of these variables present increased from 0 to 3. The impact of these modifiable risk factors was more pronounced in patients with ACS.
Discussion
The major findings of this large-scale, prospective, multicenter study are the following: (1) ST after successful DES implantation occurred in 1.1% of patients within 2 years and was associated with high rates of cardiovascular mortality (30.0%) and nonperiprocedural MI (87.2%); (2) independent baseline correlates of ST included 5 fixed variables (insulintreated diabetes mellitus, previous MI, history of dialysis, presentation with ACS, and saphenous vein graft as a target vessel; and (3) independent treatment-related correlates of ST included use of early versus later generation DES, not using IVUS for procedural guidance, and premature discontinuation of DAPT, with a trend for HPR on clopidogrel.
Nonmodifiable Risk Factors for ST
Prior studies examining correlates of ST with early-generation DES have reported varying results, possibly because of differences in study populations and variables examined, as well as the time period of ST occurrence examined. The most common fixed baseline correlates across multiple studies in a broad percutaneous coronary intervention population have included insulin-treated diabetes and presentation with ACS, followed by smoking, renal failure, younger age, small stent diameter, number and length of stents, bifurcation lesions, in-stent restenotic lesions, low ejection fraction, and the extent of CAD. 1,5-10 Peripheral arterial disease, previous MI, and saphenous vein graft lesions have also been found to be correlates of ST, but less consistently. 5,7,9 Naidu et al evaluated correlates of 1-year ST in new-generation DES (everolimuseluting stents) and found renal insufficiency and longer stent length as independent baseline correlates. 11 The fixed correlates of 2-year ST in our study were consistent with the findings from these prior studies, which primarily evaluated early-generation DES. 1,5-9 However, small stent diameter, number and length of stents, bifurcation lesions, and extent of coronary disease were not significant correlates of ST in our analysis. These differences may be explained by several novel aspects of the present study, including the broad population enrolled (51.7% and 9.5% of whom had ACS and ST-elevation myocardial infarction, respectively); the fact that all were successfully treated with DES; and the use of newer generation DES in the majority of our patients. The fixed correlates of ST in the subgroup of patients treated with new-generation DES in our study (insulin-treated diabetes mellitus and history of peripheral arterial disease) were different than those in the study by Naidu, probably related to differences in patient populations and the relatively small number of events.
Our study confirms prior reports that the rate of ST in patients with ACS is higher than that after elective stenting, [4] [5] [6] [7] although the frequency of ST at 2 years in our entire population (1.1%), in ACS patients (1.4%), and in non-ACS patients (0.8%) was lower than that in previous studies. 1 
Modifiable Risk Factors for ST
Perhaps, most importantly, the present study identifies 3 independent treatment-related risk factors for ST that may be modifiable by the patient and physician, offering the potential to improve prognosis. We previously reported that HPR on clopidogrel was an independent correlate of ST at 1 year after successful DES implantation, 12 confirming previous data. 15 At 2 years, a strong trend for the same relationship persisted in this study, but did not reach statistical significance. The present report demonstrates that HPR is strongly related to ST within 30 days, but not between 30 days and 2 years. The very strong correlation between premature discontinuation of DAPT and ST described in our study has also been a consistent finding across a wide range of studies. 1, [7] [8] [9] 11 We also previously reported the favorable impact of IVUS-guided stenting on 1-year outcomes in ADAPT-DES. 16 In the present study, IVUS-guided stenting remained a significant predictor of freedom from 2-year ST, consistent with previous data. 17 Previous observations have shown that the use of newgeneration DES is correlated with lower rates of ST. 18, 19 The present data drawn from >8500 patients across a broad clinical spectrum add to prior observations. Because new-generation DES have now replaced early-generation DES, which are no longer available, the choice of new-generation DES is no longer considered a modifiable variable.
Considering the effect of modifiable treatment-related risk factors, when 0 to 3 of these variables were present, the incidence of ST within 2 years ranged from 0.3% to 10.0%, representing a major opportunity to mitigate this devastating complication. The use of procedural IVUS guidance is under the control of the operator. Patient counseling and repeated contact may help ensure DAPT compliance for at least 6 months. Use of the potent ADP antagonists ticagrelor and prasugrel overcomes nearly all cases of HPR on clopidogrel and have been shown to reduce ST in ACS patients. 20, 21 One of these agents should thus be routinely administered in ACS patients absent contraindications, consistent with the most recent guidelines. 22 More controversial is the use of platelet function testing and potent ADP antagonists to overcome HPR in patients without ACS receiving DES. Several studies have found no benefit with high-dose clopidogrel or more potent P2Y12 inhibition after percutaneous coronary intervention in non-ACS patients with HPR on clopidogrel. [23] [24] [25] However, these studies have been limited by enrollment of low-risk patients, resulting in very low event rates and lower study power than anticipated. Several of these studies were limited by lack of 0.1 1 .0 10.0 The optimum duration of DAPT in patients receiving DES remains controversial. The recent DAPT study suggests that some patients may benefit from prolonged DAPT beyond the first year, but at the cost of increased bleeding and possibly mortality. 26 Our study does not specifically evaluate the effect of continued DAPT use after the first year, but may be helpful in identifying patients at high risk for late or very late ST in whom prolonged DAPT may be beneficial.
Model 1: Baseline Fixed Variables
MI in Patients With ST
As expected, ST events resulted in acute MI in ≈90% of patients. A novel observation from the present study is that the frequency of MI not related to ST itself was higher in patients with ST compared with patients without ST, perhaps contributed to by other predisposing factors to ST, such as HPR on clopidogrel or premature discontinuation of DAPT. Alternatively, patients with ST may be more likely to have more rapid progression of disease or incomplete revascularization, resulting in MI not related to ST. The present study was not designed to differentiate these possibilities.
Limitations
ADAPT-DES was an observational study, and although the case report form was comprehensive, there may be unmeasured variables that affect ST that are not included in our models. Selection bias in the use of IVUS-guided stenting and new-versus early-generation DES could also have influenced outcomes. Although this is the largest study evaluating predictors of ST in patients treated with DES, our cohort may still not be large enough to identify all predictors of ST. Our study antedated the general use of new antiplatelet agents (prasugrel and ticagrelor) in ACS; whether the predictors of ST are the same in patients treated with these agents is unknown. Core laboratory analysis to quantify the angiographic parameters was not routinely performed. Finally, although the present report represents a post hoc analysis, the data were collected prospectively, and ST events were adjudicated by an independent clinical events committee using original source documents.
Conclusions and Clinical Implications
Despite successful DES implantation, 1.1% of unselected patients developed ST within 2 years in this large-scale, multicenter study. Given the fact that ST was associated with high rates of MI and cardiovascular death, further efforts are warranted to reduce this infrequent but serious complication. In this regard, ST was substantially increased in patients with multiple risk factors for ST, several of which are treatmentrelated and potentially modifiable by physician and patient behavior. The present study suggests that ST in high-risk patients may be reduced with IVUS-guided stenting, potent ADP antagonists in appropriate patients to ensure sufficient inhibition of platelet activation (absent contraindications) and better strategies to achieve DAPT adherence.
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